

To: Providers

From: Jeff Robertson, Chief Medical Officer

Date: June 14, 2018

Subject: Medi-Cal and Healthy Kids Formulary Changes

Dear Providers:

Santa Clara Family Health Plan's Pharmacy and Therapeutics Committee recently conducted a therapeutic class review of short-acting insulins. Based on the review, Admelog (insulin lispro) vial and Admelog (insulin lispro) SoloSTAR pen were added to our Medi-Cal and Healthy Kids formulary to ensure coverage for safe, clinically-equivalent, and cost-effective medications.

Please consider the preferred agent, **Admelog vial or Admelog SoloSTAR pen**, as a formulary alternative for your patients.

Effective August 1, 2018, Humalog (insulin lispro) vial, Humalog (insulin lispro) U-100 KwikPen, Humalog (insulin lispro) Cartridge, Apidra (insulin glulisine) vial, and Apidra (insulin glulisine) SoloSTAR pen will no longer be covered without prior authorization. Members who currently have a prescription claim for Humalog or Apidra will receive a letter describing this formulary change. The letter will advise members to continue using the medication until they have consulted their physician.

If you have any questions about this formulary change, please contact our Pharmacy department at **1-408-874-1796.**

Thank you for your continuing care of our members!